IPDD Core Group member, LINXS Fellow

Mikael Dolsten is currently the Chief Scientific Officer and President at Worldwide Research, Development and Medical organization at Pfizer Inc., which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed medicines and vaccines.
Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden, where he was Adjunct Professor in Tumor Immunology and was recently appointed Visiting Professor to advise on science and technology strategies. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on regulatory and drug development issues as well as then Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research. Through 2019, Mikael was a council member of the GovernmentUniversity-Industry Research Roundtable. Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with contributions in molecular cell biology, immunology and oncology.